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Proposed nomenclature for CDG (nomenclature to be superseded is included in italics
and enclosed in parenthesis).a
Disease name Defective protein OMIM
A. Defects in protein N-glycosylation
PMM2-CDG (CDG-Ia) Phosphomannomutase 2 601785
MPI -CDG (CDG-Ib) Phosphomannose isomerase 602579
ALG6-CDG (CDG-Ic) Dol-P-Glc: Man9-GlcNAc2-P-P-Dol
glucosyltransferase
(glucosyltransferase 1)
603147
ALG3-CDG (CDG-Id) Dol-P-Man: Man5-GlcNAc2-P-P-Dol
mannosyltransferase
(mannosyltransferase 6)
601110
ALG12-CDG (CDG-Ig) Dol-P-Man: Man7-GlcNAc2-P-P-Dol
mannosyltransferase
(mannosyltransferase 8)
607143
ALG8-CDG (CDG-Ih) Dol-P-Glc:
Glc1-Man9-GlcNAc2-P-P-Dol
glucosyltransferase
(glucosyltransferase 2)
608104
ALG2-CDG (CDG-Ii) GDP-Man: Man1-GlcNAc2-P-P-Dol
mannosyltransferase
(mannosyltransferase 2)
607906
DPAGT1-CDG (CDG Ij) UDP-GlcNAc: Dol-P-GlcNAc-P
transferase
608093
ALG1-CDG (CDG-Ik) GDP-Man: GlcNAc2-P-P-Dol
mannosyltransferase
(mannosyltransferase 1)
608540
ALG9-CDG (CDG-Il) Dol-P-Man: Man6-and
Man8-GlcNA2-P-P-Dol
608776Congenital disorders of glycosylation (CDG) are a rapidly growing
disease family with about 40 diseases reported since its ﬁrst clinical
description in 1980 [1]. The large majority of these are diseases of
protein hypoglycosylation, but in recent years several defects in lipid
glycosylation have also been identiﬁed [2,3]. Most protein glycosyl-
ation disorders are due to defects in the N-glycosylation pathway, the
remaining ones affecting the O-glycosylation pathway or combined
N- and O-glycosylation pathways. No defects in C-glycosylation have
been detected yet. The ﬁrst described CDG patients were shown to
have an abnormal serum transferrin (Tf) isoelectrofocusing (IEF)
pattern with increases in the di- and asialotransferrin fractions [4].
They were found to have deﬁcient phosphomannomutase (PMM)
activity [5] and mutations in the PMM2 gene [6]. PMM-deﬁcient
patients were designated as CDG-Ia. Subsequently, a patient was
discovered with a serum Tf IEF pattern characterized by increases not
only of the even (2 and 0) but also of the uneven (3 and 1) sialoTf
bands [7]. Since these patterns were qualitatively different, we called
the latter a type 2 pattern as opposed to the type 1 pattern seen in
PMM deﬁciency. In the patient with the type 2 pattern, a deﬁciency
was demonstrated to be in a Golgi glycosyltransferase, namely N-
acetylglucosaminyltransferase II [8]. This disease was labeled CDG-IIa.
New patients were classiﬁed as CDG-I or CDG-II according to the Tf IEF
pattern, and each new defect took the next letter of the alphabet.
We presently count 14 CDG-I diseases (CDG-Ia up to CDG-In), and
8 CDG-II diseases (CDG-IIa up to CDG-IIh). Since this nomenclature is
based on the Tf IEF pattern, it relates only to N-glycosylation diseases
associated with deﬁcient sialylation. Gradually it became clear that
CDG-I defects were limited to defects in pre-ER or ER proteins
whereas CDG-II defects were caused by defects in Golgi or Golgi-
associated proteins. However, some of these disorders also show
abnormal O-glycosylation such as the COG defects (review in [9]) and
the V-ATPase defect in cutis laxa type II [10]. Also, it appeared that a
patient with an alpha-glucosidase I deﬁciency in the ER had a normal
Tf IEF pattern [11]. Still this patient was labeled as CDG-IIb, which is an
inconsistency of this classiﬁcation. For this reason and for a number of
other reasons explained elsewhere [12], we strongly suggest that this⁎ Corresponding author. Tel.: +32 16 343820; fax: +32 16 343842.
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doi:10.1016/j.bbadis.2009.08.005nomenclature should be discontinued in favor of a transparent
designation of glycosylation disorders and that it be applied to new
and established types of CDG. We propose using only the ofﬁcial gene
symbol (not in italics) followed by ‘-CDG’ (list of approved gene
names at http://www.genenames.org). A classiﬁcation of the known
types of CDG, along with the traditional and new nomenclature, is
shown in Table 1 (adapted from [12]).mannosyltransferase
(mannosyltransferase 7-9)
RFT1-CDG ( CDG-In) Flippase of Man5GlcNAc2-PP-Dol 611633
MGAT2-CDG (CDG-IIa) N-acetylglucosaminyltransferase 2 602616
GCS1-CDG (CDG-IIb) Glucosidase 1 606056
TUSC3-CDG Oligosaccharyltransferase subunit 601385
(continued on next page)
Table 1 (continued)
Disease name Defective protein OMIM
MGAT1-CDG Oligosaccharyltransferase subunit 300716
B. Defects in protein O-glycosylation
⁎O-xylosylglycan synthesis
- EXT1/EXT2-CDG
(multiple cartilaginous
exostoses)
Glucuronyltransferase/
N-acetylglucosaminyltransferase
608177/
608210
- B4GALT7-CDG β-1, 4-galactosyltransferase 7 604327
⁎O-N-acetylgalactosaminylglycan
synthesis
-GALNT3-CDG
(familial tumoral calcinosis)
Polypeptide
N-acetylgalactosaminyltransferase 3
601756
⁎O-xylosyl/
N-acetylgalactosaminylglycan
synthesis
-SLC35D1-CDG
(Schneckenbecken dysplasia)
Solute carrier family 35
(UDP-glucuronic acid/
UDP-N-acetylgalactosamine
dual transporter), member D1
610804
⁎O-mannosylglycan synthesis
-POMT1/POMT2-CDG (cong.
muscular dystrophy spectrum)
O-mannosyltransferase 1 607423
-POMGNT1-CDG (cong. muscular
dystrophy spectrum)
O-mannose β-1,
2-N-acetylglucosaminyltransferase
606822
-FKTN-CDG (cong. muscular
dystrophy spectrum)
Fukutin 607440
-FKRP-CDG (cong. muscular
dystrophy spectrum)
Fukutin-related protein 606596
-LARGE-CDG (cong. muscular
dystrophy spectrum)
N-acetylglucosaminyltransferase-like
protein
603590
⁎O-fucosylglycan synthesis
-LFNG-CDG (spondylocostal
dysostosis type 3)
O-fucose-speciﬁc β-1,
3-N-acetylglucosaminyltransferase
602576
-B3GALTL-CDG
(Peters plus syndrome)
O-fucose-speciﬁc β-1,
3-glucosyltransferase
610308
C. Defects in glycosphingolipid and glycosylphosphatidylinositol anchor glycosylation
ST3GAL5-CDG (Amish
infantile epilepsy)
Lactosylceramide α-2,
3 sialyltransferase (GM3 synthase)
609056
PIGM-CDG
(glycosylphosphatidylinositol
deﬁciency)
Phosphatidylinositolglycan,
class M
610273
D. Defects in multiple glycosylation and other pathways
DPM1-CDG (CDG-Ie) GDP-Man: Dol-P-mannosyltransferase
(Dol-P-Man synthase 1)
603503
MPDU1-CDG (CDG-If) Lec35 (Man-P-Dol utilization 1) 608799
B4GALT1-CDG (CDG-IId) β-1, 4-galactosyltransferase 1 607091
GNE-CDG (hereditary
inclusion body myopathy)
UDP-GlcNAc epimerase/kinase 600737
SLC35A1-CDG (CDG-IIf)
(CMP-sialic acid transporter
deﬁciency)
CMP-sialic acid transporter 605634
SLC35C1-CDG (CDG-IIc)
(GDP-fucose transporter
deﬁciency)
GDP-fucose transporter 605881
⁎Dolichol pathway -DK1-CDG
(CDG-Im)
Dolichol kinase 610768
⁎COGb complex
-COG7-CDG (CDG-IIe) Component of conserved
oligomeric Golgi complex 7
606978
-COG1-CDG (CDG-IIg) Component of conserved
oligomeric Golgi complex 1
606973
-COG8-CDG Component of conserved
oligomeric Golgi complex 8
606979
-COG4-CDG Component of conserved
oligomeric Golgi complex 4
606976
-COG5-CDG Component of conserved
oligomeric Golgi complex 5
606821
⁎ V-ATPase
-ATP6VOA2-CDG
(cutis laxa type II)
V0 subunit A2 of vesicular
H(+)-ATPase
611716
-SEC23B-CDG (CDAII) COPII component SEC23B 610512
a Adapted from [12].
b Conserved oligomeric Golgi.
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